Axsome Therapeutics price target raised to $96 from $88 at Cantor Fitzgerald

Cantor Fitzgerald analyst Charles Duncan raised the firm’s price target on Axsome Therapeutics to $96 from $88 and keeps an Overweight rating on the shares. Axsome reported Q3 revenue of $16.8M, which was in line estimates, Duncan tells investors in a research note. Axsome had a very productive quarter, highlighted by the approval of AUVELITY for MDD, and the analyst envisions AUVELITY becoming a mainstay.